Key result
Icosapent ethyl cuts major cardiovascular events by ~20% to 28% across baseline ApoB levels.
Why the study?
Does icosapent ethyl reduce major adverse cardiovascular events across different baseline apolipoprotein B and fasting triglyceride rich lipoprotein levels in statin-treated patients with elevated triglycerides and cardiovascular risk?
RCT (n=8,179)
double-blind
randomized
Yes
Does icosapent ethyl reduce major adverse cardiovascular events across different baseline apolipoprotein B and fasting triglyceride rich lipoprotein levels in statin-treated patients with elevated triglycerides and cardiovascular risk?
Answers are grounded in this paper and cite their sources.
Icosapent ethyl reduces cardiovascular risk in statin-treated patients regardless of baseline apolipoprotein B levels and across most fasting triglyceride-rich lipoprotein levels.
Background/Introduction Increased apolipoprotein B (ApoB) levels due to triglyceride rich lipoproteins (TRLs) are associated with increased cardiovascular risk, even when low-density lipoprotein cholesterol (LDL-C) levels are well controlled. In the REDUCE-IT cardiovascular outcomes trial, icosapent ethyl (IPE) showed cardiovascular risk reduction in patients with residual elevated triglycerides (TGs) persisting on statin therapy, but the impact of IPE on cardiovascular risk reduction across ApoB and TRL-cholesterol (TRL-C) strata is unclear. Purpose To study the impact of IPE on major adverse cardiovascular events (MACE) stratified by ApoB and fasting TRL-C. Methods REDUCE-IT was an international, double-blind, placebo-controlled study of 8,179 participants receiving statin therapy with established cardiovascular disease or age ≥ 50 years with diabetes and ≥ 1 additional risk factor, fasting TG level of 1.52 to 5.63 mmol/L (135 to 499 mg/dL) and LDL-C level of 1.06 to 2.59 mmol/L (41 to 100 mg/dL). Patients were randomized to receive 2 grams twice daily of IPE or matching placebo. Relationships between quartiles of baseline ApoB concentration, baseline fasting TRL-C and risk for first and total MACE were analyzed. Results Baseline ApoB and fasting TRL-C concentrations were available in 8,107 (99.1%) and 8,157 (99.7%) participants, respectively. Median baseline ApoB concentration was 0.82 g/L (IQR: 0.72 – 0.93 g/L) [82.0 mg/dL (IQR: 72.0 – 93.0 mg/dL)] and median baseline fasting TRL-C concentration was 0.80 mmol/L (IQR: 0.69 – 0.95 mmol/L) [31.0 mg/dL (IQR: 26.6 – 36.8 mg/dL)]. From the first through fourth baseline quartiles of ApoB, IPE resulted in significant reductions in MACE, HR 0.72 (95% CI 0.58, 0.88), HR 0.73 (95% CI 0.59, 0.89), HR 0.76 (95% CI 0.63, 0.91), and HR 0.80 (95% CI 0.66, 0.97), respectively (all P ≤ 0.02) (Figure 1). The first quartile of fasting TRL-C had a borderline reduction in MACE (HR 0.82, 95% CI 0.67, 1.00) (P = 0.05) (Figure 2), in contrast to significant reductions above the 25th percentile, HR 0.74 (95% CI 0.60, 0.90), HR 0.79 (95% CI 0.65, 0.96), and HR 0.68 (95% CI 0.56, 0.82), from the second through fourth quartiles, respectively (all P ≤ 0.02). Conclusion IPE significantly reduced MACE across all quartiles of baseline ApoB and TRL-C concentrations above the 25th percentile.
No takes yet. Share an insight, caveat, or question.
Malick et al. (2025) conducted an RCT in Elevated triglycerides and cardiovascular risk on statin therapy (n=8,179). Icosapent ethyl vs. matching placebo was evaluated on Major adverse cardiovascular events (MACE) (HR 0.72 to 0.80, p=≤ 0.02). Icosapent ethyl reduced major cardiovascular events across all quartiles of baseline ApoB and TRL-C concentrations above the 25th percentile.
Synapse has enriched 10 related papers. Consider them for comparative context: